Pneumagen to Present Phase 2 Neumifil Data at ATS 2024

Pneumagen, based in St Andrews, UK, is a clinical-stage biotechnology company focusing on the development of Neumifil. Neumifil is an innovative, broad-spectrum antiviral drug administered intranasally, aimed at the prevention and treatment of viral respiratory tract infections (RTIs). Pneumagen has announced that clinical results from a human challenge study involving Neumifil (HEX17) are set to be showcased at the 2024 American Thoracic Society (ATS) Conference. This event will take place both virtually and in person in San Diego, California, from May 17 to 22, 2024.

The clinical findings will be presented in both oral and ePoster sessions, highlighting crucial data regarding Neumifil's efficacy. Specifically, the results will cover Neumifil's potential to decrease the incidence of virus-induced exacerbations in patients suffering from Chronic Obstructive Pulmonary Disease (COPD).

The oral presentation, titled "HEX17, A Novel Broad-spectrum Antiviral Intranasal Drug, Demonstrates Efficacy Against Influenza in a Controlled Human Infection Model Conducted in Healthy Adults," will take place as part of the mini symposium "C18: Translating Science in Respiratory Infections." This session is scheduled for Tuesday, May 21, from 9:15 AM to 11:15 AM EST at the San Diego Convention Centre, Room 6C-F (Upper Level), and will be presented by Geoff Kitson, the Chief Medical Officer of Pneumagen.

The corresponding ePoster, carrying the same title, will be available online from Tuesday, May 21, to Friday, September 6, 2024. This poster session will also fall under the category "Translating Science in Respiratory Infections" and features authors including Geoff Kitson.

Pneumagen, established in 2016 as a spin-out from the University of St Andrews in Scotland, benefits from access to top-tier scientific expertise in viral infections, particularly in the field of glycobiology. Their lead product, Neumifil, is an engineered, multivalent Carbohydrate Binding Module (mCBM) that functions by binding directly to viral pathogens, preventing their entry into the host. This drug was developed using Pneumagen’s proprietary GlycoTarge™ technology.

Beyond Neumifil, Pneumagen is leveraging its GlycoTarge™ platform to develop a pipeline of therapies targeting other infectious diseases. This commitment to expanding their therapeutic offerings underscores the company’s dedication to addressing a wide array of infectious threats.

In summary, the forthcoming presentations at the ATS Conference will provide significant insights into Neumifil’s clinical efficacy, particularly in reducing virus-induced exacerbations in COPD patients. These presentations mark an important milestone in the development of Pneumagen's promising antiviral therapies.